Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense
research and development efforts, a large number of direct-acting antiviral drugs are now …

Treatment of chronic hepatitis C (HCV) is currently undergoing a significant change.
Traditional interferon-based therapy has been limited by both efficacy and tolerability, and …

Emerging data indicate that all‐oral antiviral treatments for chronic hepatitis C virus (HCV)
will become a reality in the near future. In replacing interferon‐based therapies, all‐oral …

Background & Aims In treatment-naive patients mono-infected with genotype 1 chronic HCV,
treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy are standard-of-care …

Introduction: About 2.35% of the world population can be infected with hepatitis C virus
(HCV) responsible for chronic hepatitis, liver cirrhosis and hepatocellular carcinoma …

During 2014 and 2015, different interferon-(IFN-) free regimens will be approved for use in
chronic hepatitis C (HCV). The liver-transplantation (LT) setting is the field of hepatology …

Current Opinion in Gastroenterology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Mutations at a number of key positions (Ala156, Asp168 and Arg155) of the HCV NS3/4A
protease can induce medium to high resistance to MK5172. The emergence of the resistant …

Background & Aims HCV-infected cirrhotics may urgently need therapy but are often under-
represented in clinical trials resulting in limited data to guide their management. We …

In recent years, several studies have clearly shown that sustained virological response
(SVR) achieved by interferon‐based therapies may delay or reduce the risk of …